Prognostic markers for CAR-T cell therapy in patients with relapsed/refractory multiple myeloma

被引：0
|
作者：
Liu, Yang [1 ]
Yan, Zhiling [2 ]
Wu, Qingyun [2 ]
Chen, Chong [2 ]
Cao, Jiang [2 ]
Li, Zhenyu [2 ]
Xu, Kailin [2 ]
机构：
[1] Xuzhou Med Univ, Dept Hematol, Affiliated Hosp, Xuzhou, Jiangsu, Peoples R China
[2] Xuzhou Med Univ, Blood Dis Inst, Xuzhou, Jiangsu, Peoples R China
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-029
引用
收藏
页码：S49 / S49
页数：1
相关论文
共 50 条
  • [1] CAR-T Therapy in Relapsed Refractory Multiple Myeloma
    Ding, Hong
    Wu, Yu
    CURRENT MEDICINAL CHEMISTRY, 2024, 31 (27) : 4362 - 4382
  • [2] CAR-T cell therapy in relapsed or refractory multiple myeloma and access in Turkey
    Hakan, Goker
    Engin, Kelkitli
    Elifcan, Karakulak Aladag
    Haluk, Demiroglu
    Mehmet, Turgut
    Suman, Kambhampati
    Maxwell, Krem
    FRONTIERS IN MEDICINE, 2024, 11
  • [3] Cost effectiveness analysis of CAR-T cell therapy for patients with relapsed/refractory multiple myeloma in China
    Wu, Weijia
    Ding, Shuyi
    Zhang, Mingming
    Zhou, Yuping
    Sun, Xueshan
    Zhao, Zixuan
    Yang, Yi
    Hu, Yongxian
    Dong, Hengjin
    JOURNAL OF MEDICAL ECONOMICS, 2023, 26 (01) : 701 - 709
  • [4] Enhanced platelet function through CAR-T cell therapy in relapsed/refractory multiple myeloma
    Ma, Ruixue
    Zhang, Qi
    Liu, Yang
    Li, Hujun
    Chen, Huimin
    Zhang, Qianqian
    Qiao, Jianlin
    Qi, Kunming
    Shen, Guifang
    Sun, Cai
    Song, Xuguang
    Cao, Jiang
    Cheng, Hai
    Zhu, Feng
    Yan, Zhiling
    Sang, Wei
    Li, Depeng
    Sun, Haiying
    Zheng, Junnian
    Li, Zhenyu
    Xu, Kailin
    Chen, Wei
    CLINICAL AND EXPERIMENTAL MEDICINE, 2024, 24 (01)
  • [5] Sequential Administration of Selinexor and CAR-T Therapy in Relapsed/ Refractory Multiple Myeloma
    Gill, Sarvarinder Kaur
    Biran, Noa
    Phull, Pooja
    Vesole, David H.
    Siegel, David S.
    Parmar, Harsh
    BLOOD, 2023, 142
  • [6] Infections associated with CAR-T cell therapy in patients with relapsed refractory multiple myeloma: Risks and prevention strategies
    An, Jing
    Zhao, Jie
    Zou, Ping
    Zhang, Yicheng
    Wei, Junni
    Tian, Weiwei
    Wei, Jia
    CANCER MEDICINE, 2024, 13 (12):
  • [7] CAR T-cell therapy for relapsed or refractory multiple myeloma
    Stirrups, Robert
    LANCET ONCOLOGY, 2019, 20 (06): : E297 - E297
  • [8] Relapsed/Refractory Multiple Myeloma Patients. a Multicenter Retrospective Analysis of Eligibility Criteria for CAR-T Cell Therapy
    Fazio, Francesca
    Di Rocco, Alice
    Za, Tommaso
    Tomarchio, Valeria
    Rago, Angela
    Piciocchi, Alfonso
    di Toritto, Tommaso Caravita
    Annibali, Ombretta
    De Stefano, Valerio
    Foa, Robin
    Martelli, Maurizio
    Petrucci, Maria Teresa
    BLOOD, 2021, 138 : 3755 - +
  • [9] Anti-BCMA CAR-T Cell Therapy in Relapsed or Refractory Multiple Myeloma Patients with Impaired Renal Function
    He, Shao-long
    Cheng, Yu-hang
    Wang, Di
    Xu, Meng-lei
    Que, Yi-mei
    Xu, Yan-jie
    Ma, Liang-ming
    Li, Chun-rui
    Zhou, Jian-feng
    CURRENT MEDICAL SCIENCE, 2021, 41 (03) : 474 - 481
  • [10] Anti-BCMA CAR-T Cell Therapy in Relapsed or Refractory Multiple Myeloma Patients with Impaired Renal Function
    Shao-long He
    Yu-hang Cheng
    Di Wang
    Meng-lei Xu
    Yi-mei Que
    Yan-jie Xu
    Liang-ming Ma
    Chun-rui Li
    Jian-feng Zhou
    Current Medical Science, 2021, 41 : 474 - 481
12345